Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole

Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole

Chagas disease remains a major social and public health problem in Latin America. Benznidazole (BZN) is the main drug with activity against <i>Trypanosoma cruzi</i>. Due to the high number of adverse drug reactions (ADRs), BZN is underprescribed. The goal of this study was to evaluate th...

Full description

Bibliographic Details
Main Authors: Lucas A. M. Franco, Carlos H. V. Moreira, Lewis F. Buss, Lea C. Oliveira, Roberta C. R. Martins, Erika R. Manuli, José A. L. Lindoso, Michael P. Busch, Alexandre C. Pereira, Ester C. Sabino
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:International Journal of Molecular Sciences
Subjects:
Chagas disease
benznidazole
adverse drug reactions
pharmacogenomics
Online Access:https://www.mdpi.com/1422-0067/22/4/1960

Internet

https://www.mdpi.com/1422-0067/22/4/1960

Similar Items